Replimune Group Inc
NASDAQ:REPL
Replimune Group Inc
NASDAQ:REPL
Price:
5.94 USD
-7.76%
Market Closed
Updated:
May 21, 2024
Replimune Group Inc
Interest Income Expense
|
Replimune Group Inc
Interest Income Expense Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Replimune Group Inc
NASDAQ:REPL
|
Interest Income Expense
$17.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Income Expense
-$1.8B
|
CAGR 3-Years
11%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Income Expense
-$663m
|
CAGR 3-Years
38%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Income Expense
-$2.9B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-16%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Income Expense
$630.1m
|
CAGR 3-Years
93%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Income Expense
$221.8m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
75%
|
CAGR 10-Years
N/A
|
See Also
What is Replimune Group Inc's Interest Income Expense?
Interest Income Expense
17.5m
USD
17.5m
USD
Based on the financial report for Dec 31, 2023, Replimune Group Inc's Interest Income Expense amounts to 17.5m USD.
What is Replimune Group Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
55%
55%
Over the last year, the Interest Income Expense growth was 1 465%.
You don't have any saved screeners yet
